Immunogenicity of Adalimumab in Patients with Non-Infectious- Uveitis: Systematic Review and Meta-Analysis

Diana Isabel Pachón-Suárez, Laura Zárate-Pinzón, Carlos Cifuentes-González, William Rojas-Carabali, Germán Mejía-Salgado, Juan Sebastián Pineda, Luisa Fernanda Peña-Pulgar, Alejandra de-la-Torre

Research output: Contribution to journalArticlepeer-review


Objective: To review the prevalence, incidence, and risk factors for developing anti-drug antibodies (AAA) in patients with non-infectious uveitis (NIU) treated with Adalimumab (ADA). Methods: A systematic literature search was performed on PubMed, EMBASE, Virtual Health Library, Cochrane, and medRxiv. Meta-analysis was performed using random effects. Results: Nine out of 2,373 studies were included. The prevalence of AAA in NIU patients treated with ADA was 9% (95% CI: 2% to 37%, I2 = 95% with a P<0.01), it was significantly higher in real-life scenarios (observational studies) than in clinical trials. The pooled incidence at 12 months was 27% (CI 95% 16%-42% I2 = 0%). Several factors have been associated with AAA generation in NIU patients, including the non-use of concomitant immunosuppressants, presence of autoimmune systemic disease, female gender, etc. Conclusion: This study showed that AAA prevalence is higher in real-life scenarios compared to clinical trials. Further research is needed to elucidate the factors that trigger AAA generation in NIU patients.

Translated title of the contributionInmunogenicidad de adalimumab en pacientes con uveítis no infecciosa: Revisión sistemática y metaanálisis
Original languageEnglish (US)
JournalOcular Immunology and Inflammation
StatePublished - Oct 5 2023

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Ophthalmology


Dive into the research topics of 'Immunogenicity of Adalimumab in Patients with Non-Infectious- Uveitis: Systematic Review and Meta-Analysis'. Together they form a unique fingerprint.

Cite this